Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients and clinicians perspectives in a clinical trial

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Faries, Douglas ^a   Ascher Svanum, Haya ^a   Phillips, Glenn ^a   Nyhuis, Allen W ^a   Sugihara, Tomoko ^b   Stauffer, Virginia ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Medfocus LLC   (United States)

Author keywords

Antipsychotic; Concurrent validity; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTERVIEW; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; METHODOLOGY; MIDDLE AGED; PILOT STUDY; PSYCHOLOGIC TEST; PSYCHOMETRY; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCHIZOPHRENIA; STANDARD;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PILOT PROJECTS; PSYCHOMETRICS; PSYCHOPATHOLOGY; PSYCHOTIC DISORDERS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SCHIZOPHRENIA;

EID: 84866126362     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-142     Document Type: Article

References (30)

1. EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lápez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, Lancet 2008 371 1085 1097 10.1016/S0140-6736(08)60486-9 18374841 (Pubitemid 351418005)
2. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, N Engl J Med 2005 353 1209 1223 10.1056/NEJMoa051688 16172203 (Pubitemid 41345943)
3. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD, Schizophr Res 2008 98 8 15 17596914 (Pubitemid 350245583)
4. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P, Am J Psychiatry 2011 168 603 609 10.1176/appi.ajp.2011. 10081224 21362741
5. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. Weiden PJ, J Clin Psychiatry 2007 68 Suppl 1 12 19 17956151
6. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann BG, Naber D, J Clin Psychiatry 2007 68 75 80 10.4088/JCP.v68n0110 17284133 (Pubitemid 46220127)
7. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. Kinon BJ, Ascher-Svanum H, Adams DH, Chen L, J Clin Psychopharmacol 2008 28 544 549 10.1097/JCP.0b013e318185e74a 18794651
8. Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Liu-Seifert H, Adams DH, Ascher-Svanum H, Faries D, Kinon BJ, Patient Prefer Adherence 2007 1 9 17 19956443
9. Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia. Liu-Seifert H, Houston JP, Adams DH, Kinon BJ, J Clin Psychopharmacol 2007 27 392 394 10.1097/01.jcp.0000264986.32733.df 17632224 (Pubitemid 47075511)
10. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, J Clin Psychiatry 2008 69 106 113 10.4088/JCP.v69n0114 18312044 (Pubitemid 351282003)
11. Developing a clinician-reported measure of reasons for antipsychotic discontinuation or continuation in the treatment of schizophrenia. Matza L, Phillips GA, Revicki D, Ascher-Svanum H, Stauffer V, Shorr J, Kinon BJ, Int J Neuropsychopharmacol 2006 9 suppl 1 153
12. Developing a patient interview to assess reasons for antipsychotic discontinuation or continuation in the treatment of schizophrenia. Matza LS, Phillips G, Revicki DA, Ascher-Svanum H, Stauffer V, Shorr JM, Kinon BJ, Schizophr Bull 2007 33 2 595 596
13. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM, Neuropsychopharmacology 2010 35 581 590 10.1038/npp.2009.164 19890258
14. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. Davis JM, Chen N, J Clin Psychiatry 2001 62 757 771 10.4088/JCP.v62n1003 11816864 (Pubitemid 33104662)
15. The positive and negative syndrome scale (PANSS) for schizophrenia. Kay SR, Fiszbein A, Opler LA, Schizophr Bull 1987 13 261 276 10.1093/schbul/13.2.261 3616518 (Pubitemid 18039085)
16. The quality of life scale: an instrument for rating the schizophrenic deficit-syndrome. Heinrichs DW, Hanlon TE, Carpenter WT, Schizophr Bull 1984 10 388 398 10.1093/schbul/10.3.388 6474101
17. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH, Schizophr Bull 2003 29 247 256 10.1093/oxfordjournals.schbul.a007001 14552500 (Pubitemid 37187688)
18. Symptom rating scales and outcomes in schizophrenia. Mortimer AM, Br J Psychiatry 2007 191 7 s14 10.1192/bjp.191.50.s7 (Pubitemid 47204549)
19. What does the PANSS mean? Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR, Schizophr Res 2005 79 231 238 10.1016/j.schres.2005.04.008 15982856 (Pubitemid 41457263)
20. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 159 174 10.2307/2529310 843571 (Pubitemid 8054849)
21. Rating of medication influences (ROMI) scale in schizophrenia. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A, Schizophr Bull 1994 20 297 310 10.1093/schbul/20.2.297 7916162 (Pubitemid 24171093)
22. Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group: Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M, J Clin Psychiatry 2004 65 312 321 10.4088/JCP.v65n0305 15096069
23. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB, Br J Psychiatry 2005 187 137 142 10.1192/bjp.187.2.137 16055824 (Pubitemid 41139685)
24. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. Weiden PJ, Daniel DG, Simpson G, Romano SJ, J Clin Psychopharmacol 2003 23 595 600 10.1097/01.jcp.0000095347.32154.08 14624190 (Pubitemid 37443191)
25. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J, Schizophr Res 2009 107 22 29 10.1016/j.schres.2008.09.031 18993031
26. Effectiveness of switching antipsychotic medications. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA, Am J Psychiatry 2006 163 2090 2095 10.1176/appi.ajp.163.12.2090 17151159 (Pubitemid 46114228)
27. CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, Am J Psychiatry 2006 163 600 610 10.1176/appi.ajp.163.4.600 16585434 (Pubitemid 44464569)
28. CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, Am J Psychiatry 2006 163 611 622 10.1176/appi.ajp.163.4.611 16585435 (Pubitemid 44464570)
29. CATIE Investigators: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, Am J Psychiatry 2007 164 415 427 10.1176/appi.ajp.164.3.415 17329466 (Pubitemid 46513155)
30. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP, Patient Prefer Adherence 2011 5 547 554 22114469